Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
Alzheimer Disease
About this trial
This is an interventional prevention trial for Alzheimer Disease focused on measuring poor sleep
Eligibility Criteria
Inclusion Criteria: Age 60-80 years Any sex Any race/ethnicity Mini-Mental Status Examination score (MMSE) ≥ 27 Positive plasma amyloid-beta test (i.e., amyloid-positive) Pittsburgh Sleep Quality Index >5 Exclusion Criteria: Cognitive impairment as determined by history of MMSE < 27 Inability to speak or understand English Any sleep disorders other than insomnia No history of moderate-to-severe sleep-disordered breathing and STOP-Bang score > 5 History or reported symptoms suggestive of restless legs syndrome, narcolepsy or other sleep disorders No more than mild sleep apnea (AHI <16) on PSG Sleep schedule outside the range of bedtime 22:00-midnight Contraindication to lumbar catheter (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery) Cardiovascular disease requiring medication except for controlled hypertension (PI discretion) Stroke Hepatic or renal impairment Pulmonary disease (PI discretion) Type 1 diabetes HIV or AIDS Neurologic or psychiatric disorder requiring medication (PI discretion) Suicidal ideations Alcohol, tobacco or marijuana use (PI discretion) Use of sedating medications (PI discretion) Inability to get out of bed independently In the opinion of the investigator, the participant should be excluded due to an abnormal physical examination. Current pregnancy Body Mass Index >35 History of migraines (PI discretion) History of drug abuse in the last 6 months History or presence of any clinically significant medical condition, behavioral or psychiatric disorder (including suicidal ideation), or surgical history based on medical record or patient report that could affect the safety of the subject or interfere with study assessments or in the judgment of the PI participant is not a good candidate. Urinary or fecal incontinence Concurrently enrolled in another trial of an investigational drug or device
Sites / Locations
- Washington University School of MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
treatment
placebo
20 participants will be randomized to take lemborexant 25mg at h.s for two consecutive nights
10 participants will be randomized to take placebo at h.s. for two consecutive nights.